Avelumab binds PD-L1 on target cells and its IgG1 Fc engages Fcγ receptor–bearing effector cells (e.g., NK cells, macrophages) to trigger ADCC/ADCP, killing PD-L1–expressing cells; PD-L1/PD-1 blockade also indirectly restores CTL-mediated killing.